COMPANY PROFILE

Botamedi

Explore full profile

Marine phytochemical-based therapeutics enhancing human and animal health with a focus on efficacy and safety

Gangneung, South KoreaFounded 2001Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2022

Total funding $500M–1B Disclosed equity funding

Unlock exact values

About Botamedi

Botamedi Inc., established in 2001, specializes in the development of therapeutics derived from marine phytochemicals. The company focuses on creating treatments that enhance the quality of life for both humans and animals by ensuring high efficacy and safety. Botamedi operates in the pharmaceutical and biotechnology sectors, targeting clients such as healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research collaborations, drug development, and the commercialization of marine phytochemical-based therapeutics. Revenue is generated through partnerships, licensing agreements, and the sale of proprietary therapeutic products. Botamedi's innovative approach addresses the limitations of conventional treatments by leveraging the inherent healing mechanisms of cells, thus minimizing side effects and maximizing therapeutic benefits.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2001
Headquarters: Gangneung, South Korea
Open positions: None listed
Dealroom signal: 21.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Mar 2022	$673M	$2.7B	DWS Group	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Botamedi website traffic

Latest recorded traffic for Botamedi is 140 monthly website visits.

Latest monthly visits140

Monthly website visitsJul 2023–Aug 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAirNexis TherapeuticsPulmonary disease therapeutics for chronic obstructive pulmonary disease	Palo Alto, United States	Operational	—	$200M	$800M
CTCallio TherapeuticsBiotechnology firm advancing multi-payload ADCs for targeted cancer therapy with innovative HER2 solutions	Seattle, United States	Operational
STSeaport TherapeuticsDeveloping new neuropsychiatric medicines, specifically antidepressants and anxiolytics	Boston, United States	Operational
SBShanghai Thermo BiotechnologyAn innovation-oriented biopharmaceutical company	China	Operational
UBUpstream BioFocuses on developing an antibody therapy for the treatment of severe asthma	Waltham, United States	Operational
APAvistone PharmaceuticalsDeveloping cancer therapies	China	Operational
STSoley TherapeuticsDrug discovery and development company using cellular responses and AI to identify novel therapies for complex diseases	Brentwood, United States	Operational
BPBoston PharmaceuticalsAcquiring and transforming innovative molecules into differentiated medicines that improve patients’ lives	Cambridge, United States	Acquired